Advances of immunotherapy-related biomarker in esophageal carcinoma.
10.3760/cma.j.cn441530-20221213-00522
- VernacularTitle:免疫治疗相关生物标志物在食管癌中的研究进展
- Author:
Rui Xiang ZHANG
1
;
Xiao Zheng KANG
1
;
Qing Feng ZHENG
1
;
Zhen WANG
1
;
Xian Kai CHEN
1
;
Yong LI
1
;
Jian Jun QIN
1
;
Yin LI
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer,Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Biomarkers;
Esophageal Neoplasms/therapy*;
Immunotherapy;
B7-H1 Antigen;
Biomarkers, Tumor
- From:
Chinese Journal of Gastrointestinal Surgery
2023;26(4):396-400
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal carcinoma is one of the most common malignant tumors in the world, with incidence and mortality rankings of 7th and 6th, respectively. In recent years, immunotherapy represented by immune checkpoint inhibitors of programmed death-1 and programmed death ligand 1 (PD-L1) has been introduced into clinical practice and has changed the treatment status of esophageal cancer. Although immunotherapy has provided long-term survival benefits for patients with advanced esophageal cancer and high pathological response rates in the neoadjuvant therapy, only a few of the patients have satisfactory therapeutic outcomes. Therefore, effective biomarkers for predicting immunotherapeutic effects are urgently needed to identify those patients who could benefit from immunotherapy. In this paper, we mainly discuss recent research advances of biomarkers related to the immunotherapy of esophageal cancer and the clinical application prospects of these biomarkers.
